Details:
NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, which is under phase 3 clinical development for the treatment of eschar, in patients with deep partial- and/or full-thickness thermal burns.
Lead Product(s): Anacaulase-bcdb
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
The supplemental funding will support replenishment of NexoBrid (Anacaulase-bcdb) previously procured for emergency preparedness, the pediatric indication sBLA submission to the U.S.FDA, and enrollment of an additional 50 patients in ongoing expanded access treatment protocol.
Lead Product(s): Anacaulase-bcdb
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 09, 2023